Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20
What Is The Global Market Value Of The Acute Myocardial Infarction Industry In 2025?
The acute myocardial infarction market has experienced robust expansion in recent years. Its value is projected to increase from $1.47 billion in 2024 to $1.56 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 5.8%. Historically, this expansion has been driven by factors such as an escalation in smoking-related heart conditions, a higher incidence of hypertension, enhancements in emergency medical services, greater understanding of heart disease risk factors, and the early adoption of aspirin in cardiovascular treatment.
The acute myocardial infarction market is projected to experience robust expansion over the coming years, reaching a valuation of $1.95 billion by 2029, driven by a compound annual growth rate (CAGR) of 5.9%. This anticipated growth during the forecast period is primarily fueled by factors such as an increasing demand for minimally invasive cardiac interventions, greater investment in regenerative medicine aimed at heart repair, the rising incidence of obesity and diabetes, and an expanding emphasis on personalized medicine for cardiovascular conditions. Key trends expected to shape the market in the forecast timeframe encompass artificial intelligence (AI)-powered early detection systems, wearable ECG monitoring devices, drug delivery utilizing nanotechnology, three-dimensional (3D) bioprinting of cardiac tissues, and sophisticated robotic-assisted cardiac surgical procedures.
Unlock Your Free Sample Report for Exclusive Market Data:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23291&type=smp
Which Drivers Are Shaping The Acute Myocardial Infarction Industry’s Market Share?
An escalation in hypertension occurrences is projected to propel the expansion of the acute myocardial infarction market moving forward. This medical condition is defined by persistently elevated blood pressure, which heightens the probability of heart disease, stroke, and other health complications. The rise in hypertension cases is attributed to the growing prevalence of inactive lifestyles, resulting from desk jobs, extended screen time, and insufficient physical activity. Hypertension contributes to acute myocardial infarction by damaging arteries, encouraging plaque formation, and increasing the risk of blood clots that can obstruct coronary arteries. For instance, in October 2024, a report from the Australian Bureau of Statistics, an Australia-based government agency, stated that the prevalence of hypertension reached 11.6% (3.0 million people) in 2022. Thus, the increasing number of hypertension cases is stimulating the growth of the acute myocardial infarction market.
What Are The Different Segment Classifications Within The Acute Myocardial Infarction Market?
The acute myocardial infarctionmarket covered in this report is segmented –
1) By Type: ST-Elevation Myocardial Infarction (STEMI); Non-ST-Elevation Myocardial Infarction (NSTEMI)
2) By Treatment Type: Thrombolytic Therapy; Percutaneous Coronary Intervention (PCI); Coronary Artery Bypass Grafting (CABG); Medications
3) By Diagnosis Method: Electrocardiogram; Cardiac Biomarkers; Echocardiography; Coronary Angiography; Magnetic Resonance Imaging (MRI); Computed Tomography (CT) Scan
4) By Route Of Administration: Oral Route; Intravenous (IV) Route; Subcutaneous Route; Transdermal Route; Sublingual Route
5) By End User: Hospitals And Clinics; Ambulatory Surgical Centers; Specialty Cardiac Centers; Research Institutes
Subsegments:
1) ST-Elevation Myocardial Infarction (STEMI): Anterior ST-Elevation Myocardial Infarction (STEMI); Inferior ST-Elevation Myocardial Infarction (STEMI); Posterior ST-Elevation Myocardial Infarction (STEMI); Lateral ST-Elevation Myocardial Infarction (STEMI); Right Ventricular ST-Elevation Myocardial Infarction (STEMI); Extensive (Large) ST-Elevation Myocardial Infarction (STEMI)
2) Non-ST-Elevation Myocardial Infarction (NSTEMI): Subendocardial Non-ST-Elevation Myocardial Infarction (NSTEMI); Partial Thickness Non-ST-Elevation Myocardial Infarction (NSTEMI); Multi-Vessel Non-ST-Elevation Myocardial Infarction (NSTEMI); Silent Non-ST-Elevation Myocardial Infarction (NSTEMI); Recurrent Non-ST-Elevation Myocardial Infarction (NSTEMI)
What Key Innovation Trends Are Fueling Advancements In The Acute Myocardial Infarction Market?
Leading companies in the acute myocardial infarction market are concentrating on securing regulatory clearances to broaden their product offerings, improve the effectiveness of treatments, and reinforce their market presence. Regulatory approvals denote official authorizations issued by health bodies like the FDA and EMA, confirming that drugs and medical devices fulfill safety, efficacy, and quality requirements before being introduced to the market. For example, in March 2025, Sungen Biomedical, a China-based biopharmaceutical firm, obtained FDA Fast Track Designation for its monoclonal antibody drug, SGC001, which is the world’s first developed for the emergency management of acute myocardial infarction (AMI). This designation acknowledges SGC001’s capability to diminish cardiomyocyte apoptosis and enhance blood flow in ischemic regions. Bolstered by promising preclinical outcomes indicating advantages in recovery and a reduction in mortality, Fast Track status allows for accelerated communication with the FDA, thereby expediting the approval process and guaranteeing faster patient access to this pioneering AMI therapy.
Who Are The Key Multinational Companies Dominating The Acute Myocardial Infarction Market?
Major companies operating in the acute myocardial infarction market are Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, Novartis AG, GSK plc, Eli Lilly and Company, Siemens Healthineers, Fujifilm Holdings Corporation, Koninklijke Philips N.V., Boston Scientific Corporation, Daiichi Sankyo Company Limited, Terumo Corporation, MicroPort Scientific Corporation, Ionis Pharmaceuticals Inc., CellProthera, Athersys Inc., BioCardia Inc., Serca Pharmaceuticals.
Download The Full Report For Exclusive Market Findings:
https://www.thebusinessresearchcompany.com/report/acute-myocardial-infarction-global-market-report
Which Region Is Projected To Lead The Acute Myocardial Infarction Market During The Forecast Period?
North America was the largest region in the acute myocardial infarction market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the acute myocardial infarction market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Version Of The Acute Myocardial Infarction Market Report:
https://www.thebusinessresearchcompany.com/customise?id=23291&type=smp
Browse Through More Reports Similar to the Global Acute Myocardial Infarction Market 2025, By The Business Research Company
Acute Myeloid Leukemia Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/acute-myeloid-leukemia-global-market-report
Acute Ischemic Stroke Drugs Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/acute-ischemic-stroke-drugs-global-market-report
Post Acute Care Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/post-acute-care-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model